In light of the findings from a recent study “In-Depth Investigation of Archival and Prospectively Collected Samples Reveals No Evidence for XMRV Infection in Prostate Cancer” (http://dx.plos.org/10.1371/journal.pone.0044954) and others in the field, the editors of PLOS Pathogens have issued a retraction of this study. The association of XMRV with prostate cancer has now been thoroughly refuted. Although the original finding of a novel gammaretrovirus, XMRV, with the use of a pan-viral detection microarray is valid, and sequencing and phylogenetic characterization of the virus still stands, the editors agree that it is clear that XMRV found in this study is laboratory-derived and there is no association of XMRV with prostate cancer. As a result the paper was retracted from PLOS Pathogens on September 18th, 2012.
Citation: Urisman A, Molinaro RJ, Fischer N, Plummer SJ, Casey G, Klein EA, et al. (2012) Retraction: Identification of a Novel Gammaretrovirus in Prostate Tumors of Patients Homozygous for R462Q RNASEL Variant. PLoS Pathog 8(9): 10.1371/annotation/7e2efc01-2e9b-4e9b-aef0-87ab0e4e4732. doi:10.1371/annotation/7e2efc01-2e9b-4e9b-aef0-87ab0e4e4732
Published: September 18, 2012
Copyright: © 2012 . This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Competing interests: No competing interests declared.